Telix Pharmaceuticals (TLX)
Commercializes prostate-cancer imaging agents while developing radiopharmaceutical diagnostics and treatments.
$11.30
vs last close−0.65 (−5.44%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.94% | 3.18M ADS | |
|---|---|---|---|
| 62 holders · as of Jun 30, 2026 | |||
| Insiders | 14.97% | 50.71M ADS | |
| 8 holders · as of Sep 14, 2026 | |||
| Other | 84.09% | 284.88M ADS | |
| remainder | |||
338.78M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
62 holders · 3.18M shares · 25 new positions · 46 increased · 8 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 561.2K | 0.17% | −3.6K | Aug 13, 2026 |
| Lazard Asset Management LLC | 284.2K | 0.08% | −5.7K | Aug 14, 2026 |
| Portland Investment Counsel Inc. | 266.2K | 0.08% | 0 | Aug 13, 2026 |
| Private Advisor Group, LLC | 197.3K | 0.06% | +22.8K | Jul 27, 2026 |
| Marshall Wace, LLP | 189.2K | 0.06% | +189.2K | Aug 13, 2026 |
| Morgan Stanley | 166.0K | 0.05% | +49.5K | Aug 13, 2026 |
| Integrated Wealth Concepts LLC | 164.4K | 0.05% | 0 | Sep 9, 2026 |
| Hennion & Walsh Asset Management, Inc. | 150.1K | 0.04% | +150.1Knew | Jul 8, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Behrenbruch Christian | 6.97% | 23.33M | 13G | Feb 14, 2025 |
| Kluge Andreas | 6.78% | 22.68M | 13G | Feb 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 7, 2026 | Darren Charlton Smithofficer: Group Chief Financial Officer | Purchase | 2,071 | $9.66 | 13,992 |
| Apr 28, 2026 | Christian Behrenbruchdirector, officer: MD & Group CEO | Purchase | 34,500 | $14.48 | 20,709,500 |
| Apr 29, 2026 | Christian Behrenbruchdirector, officer: MD & Group CEO | Purchase | 33,435 | $14.87 | 20,742,935 |
House and Senate disclosures
Not reported.